Notifications Bell

Markets extend their rally over Pfizer’s full FDA approval - Tuesday Review, August 24

Markets extend their rally over Pfizer’s full FDA approval - Tuesday Review, August 24

German economic data showed the GDP rose more than expected in Q2

The US

Wall Street ended higher, as the FDA’s full approval of a COVID-19 vaccine and the absence of negative catalysts kept risk appetite alive ahead of the Jackson Hole Symposium. USA30 rose 0.09%, and USA500 gained 0.15%. TECH100 added 0.52%.

Crude oil went up 1.1% at $66.39 a barrel.

Gold rose 0.2% to $1,803.15 per ounce.

Asia and Australia

Stocks were up, boosted by the FDA’s approval of the COVID-19 vaccine, which is expected to increase US vaccination rates and assuage concerns over the virus’s impact on global economic recovery.

Japan225 rose 1.12%.

HongKong45 was up 0.28%.

Down under, Australia200 traded 0.28% higher.


Markets closed in the green, helped by stronger than expected German growth and the full US approval of the Pfizer-BioNTech COVID-19 vaccine.

Germany30 traded 0.2% higher. France40 and UK100 each added 0.1%.

Brent oil rose 1.2% to $69.19 per barrel.

EUR/USD lost 0.1% trading at 1.1737.


The information presented herein is prepared by and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance and forecasts are not reliable indicators of future results.